๐ฐ Between Mar News
Between Mar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Between Mar. Real-time updates on events, politics, business and more.
May 4, 2024
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer serious adverse events in the semaglutide group. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity and diabetes lead to poor prognosis in patients with heart failure. GLP-1 receptor agonists, such as semaglutide, have been shown
April 3, 2024
1. Novel assay, NG-LFA, showed strong sensitivity and specificity compared to NG-PCR in both urine and vaginal specimens. 2. NG-MAST showed 93 different sequence types out of 156 LFA-positive specimens. Evidence Rating Level: 2 (Good) Study Rundown: To address the need for a rapid and cost-effective point-of-care test, a Neisseria gonorrhoeae novel lateral flow assay
November 28, 2023
The buildings have a total floor space of 50,000 square metres, but there are some concerns it may still not be enough as the capital of the Costa del Sol continues to at
October 5, 2023
Siriwipa Pansukย was handed 168 new charges - the bulk of which were for cheating - while Pi Jianpeng was given two fresh charges.
September 21, 2023
1. Monthly migraine days were significantly reduced in atogepant 30 mg twice daily and atogepant 60 mg once daily groups compared to placebo. 2. The frequency of acute medication use for headaches was reduced among patients receiving atogepant compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Migraine is a chronic neurological disease affecting
August 29, 2023
1. Body weight reduction at week 72 was significantly greater with tirzepatide versus placebo. 2. Hemoglobin A1c was significantly reduced with tirzepatide versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is a chronic disease that is expected to affect nearly 2 billion people by 2035. Although weight reduction is a key component of
July 12, 2023
1. 5-year ipsilateral breast tumor relapse rates for test group 1 were non-inferior to the control group. However, noninferiority was not shown with test group 2 versus control. 2. Test group 2 was found to have a higher rate of moderate or marked breast induration compared to the control group and test group 1. Evidence
July 5, 2023
1. All-cause and cardiovascular mortality rates were greater in the 24h systolic blood pressure group than clinic systolic blood pressure group. 2. Night-time systolic blood pressure was most predictive of all-cause and cardiovascular mortality. Evidence Rating Level: 2 (Good) Study Rundown: Hypertension is often known as one of the leading causes of cardiovascular morbidity and
July 5, 2023
1. All-cause and cardiovascular mortality rates were greater in the 24h systolic blood pressure group than clinic systolic blood pressure group. 2. Night-time systolic blood pressure was most predictive of all-cause and cardiovascular mortality. Evidence Rating Level: 2 (Good) Study Rundown: Hypertension is often known as one of the leading causes of cardiovascular morbidity and mortality. While
April 5, 2023
1. Adverse pregnancy outcomes were less frequent among patients in the sulfadoxine-pyrimethamine group. 2. Differences in adverse pregnancy outcomes were mainly driven by an increased incidence of low birth weight and small for gestational age pregnancies. Evidence Rating Level: 1 (Excellent) Study Rundown: Plasmodium falciparum malaria infection can have adverse maternal and fetal outcomes. Studies